Peripheral blood mRNA expressions of stress biomarkers in manic episode and subsequent remission

Psychoneuroendocrinology

Volumn 70, Issue , 2016, Pages 10-16

  Köse Çinar, Rugül ^a   Sönmez, Mehmet Bülent ^a   Görgülü, Yasemin ^a  

^a TRAKYA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Bipolar disorder; Brain derived neurotrophic factor; Glucocorticoid receptor; Heat shock protein 70; Tissue plasminogen activator; Tumour necrosis factor alpha

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; GLUCOCORTICOID RECEPTOR; HEAT SHOCK PROTEIN 70; MESSENGER RNA; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; CYTOKINE; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BIPOLAR DISORDER; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; MALE; MANIA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; BIOSYNTHESIS; BLOOD; GENETICS;

ADULT; BIOMARKERS; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; CYTOKINES; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MALE; RECEPTORS, GLUCOCORTICOID; RNA, MESSENGER; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84966454892     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2016.04.020     Document Type: Article

References (66)

1. Bahi A., Dreyer J.L. Hippocampus-specific deletion of tissue plasminogen activator tPA in adult mice impairs depression- and anxiety-like behaviors. Eur. Neuropsychopharmacol. 2012, 22:672-682.
2. Bei E.S., Salpeas V., Alevizos B., Anagnostara C., Pappa D., Moutsatsou P. Pattern of heat shock factor and heat shock protein expression in lymphocytes of bipolar patients: increased HSP70-glucocorticoid receptor heterocomplex. J. Psychiatr. Res. 2013, 47:1725-1736.
3. Belmaker R.H. Bipolar disorder. N. Engl. J. Med. 2004, 351:476-486.
4. Belvederi Murri M., Prestia D., Mondelli V., Pariante C., Patti S., Olivieri B., Arzani C., Masotti M., Respino M., Antonioli M., Vassallo L., Serafini G., Perna G., Pompili M., Amore M. The HPA axis in bipolar disorder: systematic review and meta-analysis. Psychoneuroendocrinology 2015, 63:327-342.
5. Berk M., Ng F., Wang W.V., Calabrese J.R., Mitchell P.B., Malhi G.S., Tohen M. The empirical redefinition of the psychometric criteria for remission in bipolar disorder. J. Affect. Disord. 2008, 106:153-158.
6. Brietzke E., Mansur R.B., Soczynska J.K., Kapczinski F., Bressan R.A., McIntyre R.S. Towards a multifactorial approach for prediction of bipolar disorder in at risk populations. J. Affect. Disord. 2012, 140:82-91.
7. Castorina A., Waschek J.A., Marzagalli R., Cardile V., Drago F. PACAP interacts with PAC1 receptors to induce tissue plasminogen activator (tPA) expression and activity in schwann cell-like cultures. PLoS One 2015, 10:e0117799.
8. Chiu C.T., Wang Z., Hunsberger J.G., Chuang D.M. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol. Rev. 2013, 65:105-142.
9. Chuang D.M. The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Ann. N. Y. Acad. Sci. 2005, 1053:195-204.
10. Domingueti C.P., Dusse L.M., Carvalho M.D., de Sousa L.P., Gomes K.B., Fernandes A.P. Diabetes mellitus: the linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. J. Diab. Complications 2016, 30:738-745.
11. Duffy A., Jones S., Goodday S., Bentall R. Candidate risks indicators for bipolar disorder: early intervention opportunities in high-risk youth. Int. J. Neuropsychopharmacol. 2015, 19. 10.1093/ijnp/pyv071.
12. Esser N., Paquot N., Scheen A.J. Inflammatory markers and cardiometabolic diseases. Acta Clin. Belg. 2015, 70:193-199.
13. Fernandes B.S., Molendijk M.L., Kohler C.A., Soares J.C., Leite C.M., Machado-Vieira R., Ribeiro T.L., Silva J.C., Sales P.M., Quevedo J., Oertel-Knochel V., Vieta E., Gonzalez-Pinto A., Berk M., Carvalho A.F. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies. BMC Med. 2015, 13:289.
14. Fernandez-Funez P., Rincon-Limas D.E. Launching Hsp70 neuroprotection: two drugs better than one. Cell Cycle 2014, 13:1657-1658.
15. Fiedorowicz J.G., Coryell W.H., Rice J.P., Warren L.L., Haynes W.G. Vasculopathy related to manic/hypomanic symptom burden and first-generation antipsychotics in a sub-sample from the collaborative depression study. Psychother. Psychosom. 2012, 81:235-243.
16. Fillman S.G., Sinclair D., Fung S.J., Webster M.J., Shannon Weickert C. Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder. Transl. Psychiatry 2014, 4:e365.
17. Frey B.N., Andreazza A.C., Houenou J., Jamain S., Goldstein B.I., Frye M.A., Leboyer M., Berk M., Malhi G.S., Lopez-Jaramillo C., Taylor V.H., Dodd S., Frangou S., Hall G.B., Fernandes B.S., Kauer-Sant'Anna M., Yatham L.N., Kapczinski F., Young L.T. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust. N. Z. J. Psychiatry 2013, 47:321-332.
18. Goldstein B.I., Young L.T. Toward clinically applicable biomarkers in bipolar disorder: focus on BDNF, inflammatory markers, and endothelial function. Curr. Psychiatry Rep. 2013, 15:425.
19. Gray J.D., Milner T.A., McEwen B.S. Dynamic plasticity: the role of glucocorticoids, brain-derived neurotrophic factor and other trophic factors. Neuroscience 2013, 239:214-227.
20. Gross C., Blasey C.M., Roe R.L., Allen K., Block T.S., Belanoff J.K. Mifepristone treatment of olanzapine-induced weight gain in healthy men. Adv. Ther. 2009, 26:959-969.
21. He J., Kong J., Tan Q.R., Li X.M. Neuroprotective effect of atypical antipsychotics in cognitive and non-cognitive behavioral impairment in animal models. Cell Adhes. Migr. 2009, 3:129-137.
22. Hoirisch-Clapauch S., Nardi A.E., Gris J.C., Brenner B. Mental disorders and thrombotic risk. Semin. Thromb. Hemost. 2013, 39:943-949.
23. Jackson J.G., Diaz F.J., Lopez L., de Leon J. A combined analysis of worldwide studies demonstrates an association between bipolar disorder and tobacco smoking behaviors in adults. Bipolar Disord. 2015, 17:575-597.
24. Jeanneteau F., Chao M.V. Are BDNF and glucocorticoid activities calibrated?. Neuroscience 2013, 239:173-195.
25. Jin K., Zhu Y., Sun Y., Mao X.O., Xie L., Greenberg D.A. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:11946-11950.
26. Juster R.P., McEwen B.S., Lupien S.J. Allostatic load biomarkers of chronic stress and impact on health and cognition. Neurosci. Biobehav. Rev. 2010, 35:2-16.
27. Kapczinski F., Vieta E., Andreazza A.C., Frey B.N., Gomes F.A., Tramontina J., Kauer-Sant'anna M., Grassi-Oliveira R., Post R.M. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci. Biobehav. Rev. 2008, 32:675-692.
28. Kapczinski F., Dal-Pizzol F., Teixeira A.L., Magalhaes P.V., Kauer-Sant'Anna M., Klamt F., Moreira J.C., de Bittencourt Pasquali M.A., Fries G.R., Quevedo J., Gama C.S., Post R. Peripheral biomarkers and illness activity in bipolar disorder. J. Psychiatr. Res. 2011, 45:156-161.
29. Kim M., Kim S.O., Lee M., Park Y., Kim D., Cho K.H., Kim S.Y., Lee E.H. Effects of ginsenoside Rb1 on the stress-induced changes of BDNF and HSP70 expression in rat hippocampus. Environ. Toxicol. Pharmacol. 2014, 38:257-262.
30. Kruithof E.K., Dunoyer-Geindre S. Human tissue-type plasminogen activator. Thromb. Haemost. 2014, 112:243-254.
31. Lakshminarasimhan H., Chattarji S. Stress leads to contrasting effects on the levels of brain derived neurotrophic factor in the hippocampus and amygdala. PLoS One 2012, 7:e30481.
32. Larsson P., Ulfhammer E., Magnusson M., Bergh N., Lunke S., El-Osta A., Medcalf R.L., Svensson P.A., Karlsson L., Jern S. Role of histone acetylation in the stimulatory effect of valproic acid on vascular endothelial tissue-type plasminogen activator expression. PLoS One 2012, 7:e31573.
33. Leboyer M., Soreca I., Scott J., Frye M., Henry C., Tamouza R., Kupfer D.J. Can bipolar disorder be viewed as a multi-system inflammatory disease. J. Affect. Disord. 2012, 141:1-10.
34. Leelahanaj T., Kongsakon R., Choovanichvong S., Tangwongchai S., Paholpak S., Kongsuk T., Srisurapanont M., Thai Bipolar Registry Study G. Time to relapse and remission of bipolar disorder: findings from a 1-year prospective study in Thailand. Neuropsychiatr. Dis. Treat. 2013, 9:1249-1256.
35. Lepping P., Delieu J., Mellor R., Williams J.H., Hudson P.R., Hunter-Lavin C. Antipsychotic medication and oxidative cell stress: a systematic review. J. Clin. Psychiatry 2011, 72:273-285.
36. Li Q., Ford M.C., Lavik E.B., Madri J.A. Modeling the neurovascular niche: VEGF- and BDNF-mediated cross-talk between neural stem cells and endothelial cells: an in vitro study. J. Neurosci. Res. 2006, 84:1656-1668.
37. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
38. Lukasiewicz M., Gerard S., Besnard A., Falissard B., Perrin E., Sapin H., Tohen M., Reed C., Azorin J.M., Emblem Study G. Young mania rating scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort. Int. J. Methods Psychiatr. Res. 2013, 22:46-58.
39. Machado-Vieira R., Soeiro-De-Souza M.G., Richards E.M., Teixeira A.L., Zarate C.A. Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach. World J. Biol. Psychiatry 2014, 15:84-95.
40. Maletic V., Raison C. Integrated neurobiology of bipolar disorder. Front. Psychiatry 2014, 5:98.
41. Martinez de Toda I., De la Fuente M. The role of Hsp70 in oxi-inflamm-aging and its use as a potential biomarker of lifespan. Biogerontology 2015, 16:709-721.
42. McEwen B.S. Central effects of stress hormones in health and disease: understanding the protective and damaging effects of stress and stress mediators. Eur. J. Pharmacol. 2008, 583:174-185.
43. Melchor J.P., Pawlak R., Strickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (abeta) degradation and inhibits abeta-induced neurodegeneration. J. Neurosci. 2003, 23:8867-8871.
44. Nakahashi T., Fujimura H., Altar C.A., Li J., Kambayashi J., Tandon N.N., Sun B. Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor. FEBS Lett. 2000, 470:113-117.
45. Nciri R., Bourogaa E., Jbahi S., Allagui M.S., Elfeki A., Vincent C., Croute F. Chronic neuroprotective effects of low concentration lithium on SH-SY5Y cells: possible involvement of stress proteins and gene expression. Neural Regen. Res. 2014, 9:735-740.
46. Oertelt-Prigione S. Immunology and the menstrual cycle. Autoimmun. Rev. 2012, 11:A486-492.
47. Pang P.T., Teng H.K., Zaitsev E., Woo N.T., Sakata K., Zhen S., Teng K.K., Yung W.H., Hempstead B.L., Lu B. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 2004, 306:487-491.
48. Pawlak R., Rao B.S., Melchor J.P., Chattarji S., McEwen B., Strickland S. Tissue plasminogen activator and plasminogen mediate stress-induced decline of neuronal and cognitive functions in the mouse hippocampus. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:18201-18206.
49. Prieto M.L., Schenck L.A., Kruse J.L., Klaas J.P., Chamberlain A.M., Bobo W.V., Bellivier F., Leboyer M., Roger V.L., Brown R.D., Rocca W.A., Frye M.A. Long-term risk of myocardial infarction and stroke in bipolar I disorder: a population-based cohort study. J. Affect. Disord. 2016, 194:120-127.
50. Rani V., Deep G., Singh R.K., Palle K., Yadav U.C. Oxidative stress and metabolic disorders: pathogenesis and therapeutic strategies. Life Sci. 2016, 148:183-193.
51. Ray M.T., Shannon Weickert C., Webster M.J. Decreased BDNF and TrkB mRNA expression in multiple cortical areas of patients with schizophrenia and mood disorders. Transl. Psychiatry 2014, 4:e389.
52. Revest J.M., Le Roux A., Roullot-Lacarriere V., Kaouane N., Vallee M., Kasanetz F., Rouge-Pont F., Tronche F., Desmedt A., Piazza P.V. BDNF-TrkB signaling through Erk1/2 MAPK phosphorylation mediates the enhancement of fear memory induced by glucocorticoids. Mol. Psychiatry 2014, 19:1001-1009.
53. Rizzo L.B., Costa L.G., Mansur R.B., Swardfager W., Belangero S.I., Grassi-Oliveira R., McIntyre R.S., Bauer M.E., Brietzke E. The theory of bipolar disorder as an illness of accelerated aging: implications for clinical care and research. Neurosci. Biobehav. Rev. 2014, 42:157-169.
54. Rodier M., Prigent-Tessier A., Bejot Y., Jacquin A., Mossiat C., Marie C., Garnier P. Exogenous t-PA administration increases hippocampal mature BDNF levels. Plasmin- or NMDA-dependent mechanism?. PLoS One 2014, 9:e92416.
55. Rosenblat J.D., McIntyre R.S. Are medical comorbid conditions of bipolar disorder due to immune dysfunction?. Acta Psychiatr. Scand. 2015, 132:180-191.
56. Rothman S.M., Mattson M.P. Activity-dependent, stress-responsive BDNF signaling and the quest for optimal brain health and resilience throughout the lifespan. Neuroscience 2013, 239:228-240.
57. Santoro M.G. Heat shock factors and the control of the stress response. Biochem. Pharmacol. 2000, 59:55-63.
58. Scola G., Andreazza A.C. The role of neurotrophins in bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2015, 56:122-128.
59. Sies H. Oxidative Stress and Inflammatory Mechanisms in Obesity Diabetes, and the Metabolic Syndrome 2007, CRC Press.
60. Sinclair D., Tsai S.Y., Woon H.G., Weickert C.S. Abnormal glucocorticoid receptor mRNA and protein isoform expression in the prefrontal cortex in psychiatric illness. Neuropsychopharmacology 2011, 36:2698-2709.
61. Sodersten K., Palsson E., Ishima T., Funa K., Landen M., Hashimoto K., Agren H. Abnormality in serum levels of mature brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in mood-stabilized patients with bipolar disorder: a study of two independent cohorts. J. Affect. Disord. 2014, 160:1-9.
62. Suri D., Vaidya V.A. Glucocorticoid regulation of brain-derived neurotrophic factor: relevance to hippocampal structural and functional plasticity. Neuroscience 2013, 239:196-213.
63. Suzuki Y., Nagai N., Yamakawa K., Muranaka Y., Hokamura K., Umemura K. Recombinant tissue-type plasminogen activator transiently enhances blood-brain barrier permeability during cerebral ischemia through vascular endothelial growth factor-mediated endothelial endocytosis in mice. J. Cereb. Blood Flow Metab. 2015, 35:2021-2031.
64. Wiley J.W., Higgins G.A., Athey B.D. Stress and glucocorticoid receptor transcriptional programming in time and space: implications for the brain-gut axis. Neurogastroenterol. Motil. 2016, 28:12-25.
65. Yepes M. Tissue-type plasminogen activator is a neuroprotectant in the central nervous system. Front. Cell. Neurosci. 2015, 9:304.
66. Yu W.W., Bao X.Q., Sun H., Zhang D. [The role of heat shock protein 70 in regulating neuroinflammation]. Yao Xue Xue Bao 2015, 50:945-950.